Clinical Trials Logo

Filter by:
NCT ID: NCT04309474 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Start date: November 9, 2020
Phase: Phase 2
Study type: Interventional

Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess change in neurologic function in participants following an acute ischemic stroke. Elezanumab is an investigational drug being developed for the treatment of acute ischemic stroke. This 52-week study is "double-blinded', which means that neither the participants nor the study doctors will know who will be given elezanumab and who will be given placebo (does not contain treatment drug). Participants will be assigned to one of two groups, called treatment arms. Participants in one arm will receive elezanumab and participants in the other arm will receive placebo. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 120 subjects will be enrolled in 45 sites worldwide. Participants will be randomized to elezanumab or placebo by intravenous (IV) infusion within 24 hours of "last known normal" (time when the participant was last known to be without signs and symptoms of the current stroke) and every 4 weeks thereafter for 48 weeks for a total of 13 doses. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of elezanumab will be checked by medical assessments, blood tests, evaluation of side effects, and completion of questionnaires.

NCT ID: NCT04309396 Active, not recruiting - SIBO Clinical Trials

Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)

AIRE
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Small intestinal bacterial overgrowth (SIBO) is defined as a condition in which an abnormally high amount of coliform bacteria is present in the small bowel and results in premature anaerobic fermentation of carbohydrates before reaching the colon. Commonly recognized causes include gastric achlorhydria, post-surgical bowel stasis, gastrocolic/coloenteric fistulas, and motility disorders leading to bowel stasis.. The current "gold standard" for the diagnosis of SIBO, is a breath test that measures the concentration of hydrogen in response to lactulose, a carbohydrate that is only metabolized by bacteria. However, its accuracy is only about 50% and therefore it is not a very useful test, leading most physicians to treat these patients empirically based on clinical suspicion alone. The purpose of this study is to evaluate the clinical utility of a portable medical device called AIRE, an over-the-counter, commercially available handheld breath analyzer that measures exhaled hydrogen content.

NCT ID: NCT04309266 Active, not recruiting - Hemiparesis Clinical Trials

The Impact of Robot Assisted Therapy and Metacognitive Skills Training for Children With Hemiparesis

Start date: January 11, 2021
Phase: N/A
Study type: Interventional

The Occupational Therapy Department at Boston Children's Hospital is teaming up with MGH Institute of Health Professions to explore the benefits of using robot assisted therapy (Amadeo) and a problem solving approach (Active Learning Program for Stroke) to achieving functional goals for children ages 7-17 years old that have hemiparesis. The hope is to help participants make gains in both hand/arm skills and progress in everyday activities such as self-care, play, school and work. Participation will look like regular therapy with sessions 3 times weekly for 8 weeks. Each visit will include time for games on the Amadeo and time spent problem solving current activity challenges for each child. Families are encouraged to participate.

NCT ID: NCT04309188 Active, not recruiting - Sports Performance Clinical Trials

Stroboscopic Vision Training in Softball

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Enhanced sports performance, in our current world, is being pushed at the professional level and down to school-age children as well. Money is being spent on lessons and equipment to enhance performance. One new method to enhance performance is stroboscopic vision goggles. The glasses lenses flicker removing visual information for a brief moment. The claim is that they train connections between the eyes, brain, and body. We want to see if this product truly does enhance visual performance during a softball season for high school girls.

NCT ID: NCT04309084 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Start date: May 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.

NCT ID: NCT04308759 Active, not recruiting - Clinical trials for Cigarette Smoking-Related Carcinoma

An Innovative Conversational Agent (Quitbot) for Smoking Cessation

Start date: July 24, 2022
Phase: Phase 3
Study type: Interventional

This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.

NCT ID: NCT04308590 Active, not recruiting - Hypercortisolism Clinical Trials

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

GRADIENT
Start date: July 27, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance and/or uncontrolled systolic hypertension.

NCT ID: NCT04308473 Active, not recruiting - Dietary Habits Clinical Trials

Analysis of MicroBial Metabolites After Eating Refined Food

AMBER
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about what happens in the human body after consuming a meal that contains ultra-processed foods like hamburgers, and if this is different to what happens after consuming a meal that contains lots of whole foods, like fresh vegetables, instead.

NCT ID: NCT04308109 Active, not recruiting - Clinical trials for Tracheostomy Complication

Simulation Training in the Pediatric Tracheostomy and Home Ventilator Population

Start date: September 22, 2017
Phase: N/A
Study type: Interventional

The investigators will develop, refine and pilot a highly-realistic simulation program that will allow caregivers opportunities to manage critical situations as it pertains to a medically complex child dependent on tracheostomy with or without home ventilation. The investigators hope to demonstrate that the use of highly realistic simulation training will improve hospital utilization as caregivers will have a more realistic understanding of clinical and equipment-related emergencies that may occur outpatient.

NCT ID: NCT04307381 Active, not recruiting - Clinical trials for Hereditary Angioedema

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Start date: April 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).